Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Pharma & Biotech
Pharma & Biotech
Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Pharma & Biotech
Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?
GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.
Pharma & Biotech
What Caliway’s CBL-514 and tirzepatide combination data could reveal about obesity treatment next
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Medical Devices & Diagnostics
Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.
Pharma & Biotech
Novo Nordisk’s CagriSema misses non-inferiority against tirzepatide: Why a 23% weight loss still reshapes the obesity pipeline
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Features & Analysis
Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can
Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)
Pharma & Biotech
What OrsoBio’s Phase 1b/2a TLC-6740 results reveal about the limits of GLP-1 monotherapy
OrsoBio’s TLC-6740 combo data hints at a new way to break GLP-1 plateaus. Read what this could change in obesity drug development.
Pharma & Biotech
Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?
Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.